Pub. Date : 2021 Oct 22
PMID : 34686712
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement. | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |
| 2 | In patients with ALK and ROS1 genes alteration, the median overall survival was 34 months in crizotinib treated patients and 6 months in patients who received chemotherapy (HR = 0.266, p = 0.0056). | Crizotinib | ROS proto-oncogene 1, receptor tyrosine kinase | Homo sapiens |